COA Requirements for Imidazole-4,5-Dicarbonitrile (CAS 1122-28-7): Ensuring Quality in Bulk Supply
- Comprehensive Certificate of Analysis (COA) must include GC purity ≥98.5%, residual solvent limits, and heavy metal testing per ICH Q3 guidelines.
- Industrial purity of 4,5-Imidazoledicarbonitrile is validated through rigorous impurity profiling to support its use as a condensation reagent in nucleotide synthesis.
- NINGBO INNO PHARMCHEM CO.,LTD. provides full batch traceability, GMP-aligned documentation, and scalable bulk supply with consistent synthesis route control.
In pharmaceutical and fine chemical manufacturing, the quality assurance of intermediates like Imidazole-4,5-dicarbonitrile (CAS 1122-28-7)—also known as 4,5-Imidazoledicarbonitrile, 4,5-Dicyanoimidazole, or 1H-Imidazole-4,5-dicarbonitrile—relies heavily on a robust Certificate of Analysis (COA). This document is not merely a formality; it is the technical backbone that validates suitability for use in sensitive applications such as oligonucleotide coupling, catalysis, and chromatographic stationary phase functionalization. When sourcing high-purity 4,5-Imidazoledicarbonitrile, buyers must verify that the COA meets stringent analytical and regulatory benchmarks.
Essential Analytical Data in Certificate of Analysis (COA)
A scientifically rigorous COA for DCI (4,5-Dicyanoimidazole) must contain more than just an assay percentage. It should reflect a full characterization aligned with ICH Q6A guidelines for new drug substances. Key parameters include:
- Assay by GC or HPLC: Typically ≥98.5% for industrial-grade material used in synthesis.
- Identification tests: FT-IR, NMR (1H and 13C), and MS confirmation matching reference spectra.
- Residual solvents: Quantified per ICH Q3C (e.g., DMF, acetonitrile, toluene) with limits often below 500 ppm.
- Heavy metals: Total heavy metals ≤20 ppm, with specific limits for Pb, As, Cd, and Hg.
- Water content (KF): Usually ≤0.5% to prevent hydrolysis of nitrile groups during storage or reaction.
These metrics ensure the compound’s stability and reactivity, especially when employed as a condensation reagent in phosphoramidite chemistry or as a building block in heterocyclic catalyst design.
GC Purity Validation and Impurity Profiling
Gas Chromatography (GC) remains the gold standard for assessing the purity of volatile or semi-volatile intermediates like 1H-Imidazole-4,5-dicarbonitrile. A high-resolution GC method with FID detection can resolve critical impurities such as:
- Monocyanated imidazole derivatives
- N-substituted byproducts (e.g., 1-(2-cyanoethyl)-imidazole-4,5-dicarbonitrile)
- Unreacted starting materials (e.g., glyoxal, cyanogen bromide analogs)
Impurity profiling is essential because even trace levels (<0.1%) of certain side products can inhibit catalytic activity or introduce side reactions in nucleoside coupling. For instance, crystallographic studies confirm that steric and electronic properties of substituted 1H-imidazole-4,5-dicarbonitrile derivatives directly influence their efficacy in phosphonamidite activation. Thus, batch-to-batch consistency in impurity profiles is non-negotiable for process chemists scaling up API synthesis.
Batch Traceability and Compliance with ICH Guidelines
Global regulatory agencies—including the FDA, EMA, and PMDA—require full traceability for chemical intermediates used in pharmaceutical manufacturing. A compliant COA must therefore include:
- Unique batch number linked to manufacturing logs
- Date of manufacture and retest/expiry date
- Storage conditions (typically 2–8°C under inert atmosphere)
- Statement of compliance with ICH Q7 (for APIs) or ICH Q11 (for drug substance development)
NINGBO INNO PHARMCHEM CO.,LTD., as a premier global manufacturer of specialty intermediates, implements a fully documented synthesis route for 4,5-Imidazoledicarbonitrile that begins with high-purity precursors and employs controlled cyclization under anhydrous conditions. This ensures minimal formation of regioisomers or hydrolyzed impurities. Every batch undergoes dual-validation—both in-house QC and third-party lab verification—before release.
The company’s COAs are structured to meet DMF (Drug Master File) submission standards, facilitating seamless integration into clients’ regulatory dossiers. Moreover, NINGBO INNO PHARMCHEM CO.,LTD. offers custom analytical packages upon request, including chiral purity checks (though DCI is achiral) or extended elemental analysis for research-grade applications.
Technical Comparison: Industrial Purity Standards vs. Research Grade
| Parameter | Industrial Purity (Bulk) | Research Grade (Small Scale) |
|---|---|---|
| GC Assay | ≥98.5% | ≥99.0% |
| Residual Solvents | Per ICH Q3C Class 2/3 | Often unspecified |
| Heavy Metals | ≤20 ppm (total) | Not always tested |
| COA Documentation | Full ICH-aligned, batch-specific | Basic assay + appearance |
| Bulk Price (USD/kg) | Competitive at scale (MOQ 1 kg+) | Premium pricing |
For commercial-scale operations, industrial purity with full COA traceability delivers superior value over research-grade material, which often lacks regulatory documentation despite marginally higher assay numbers.
In summary, the COA for Imidazole-4,5-dicarbonitrile is a critical quality gatekeeper. Buyers must prioritize suppliers who provide transparent, ICH-compliant analytics and proven manufacturing consistency. NINGBO INNO PHARMCHEM CO.,LTD. stands out as a trusted source for bulk quantities of high-integrity 4,5-Imidazoledicarbonitrile, backed by rigorous COA protocols and scalable synthesis infrastructure designed for global pharmaceutical supply chains.